Website Search
ID 2182
Alzheimer's disease therapy - clinical trials
Description:
Professor Donna Wilcock discusses the process of going from a mouse model to human trials for testing the amyloid beta immunization for Alzheimer's disease.
Transcript:
Right now, as of today [November, 2008], the drug companies are in phase II and phase III clinical trials of something a little more complex than the a-beta [amyloid beta] vaccination, which is to directly administer anti-a-beta antibodies to people. The idea is that this is a safer approach than a vaccination approach because you can withdraw treatment if you see any adverse effects. So, the antibody – and we call this passive immunization – passive immunization is in phase II to phase III, and there are at the moment, to my understanding, three drug companies with three different antibodies in trials. And then the a-beta vaccination approach, which is an active vaccination, this approach is in very early phase II trials right now.
Keywords:
alzheimer, treatment, vaccine, immunization, phase, human, clinical, trial, antibody, vaccination, therapy, donna, wilcock
Downloads:
This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.Related content:
- 1304. Alzheimer's Disease Vaccine?
- PBS's 'Secret Life of the Brain' reviews research on the prevention and treatment of Alzheimer's disease.
- SOURCE: G2C
- 2180. Immunotherapy fights Alzheimer's disease
- Professor Donna Wilcock discusses an exciting finding from her research group that uses immunotherapy to prevent neurofibrillary tangles in mice.
- SOURCE: G2C
- 796. New Treatments for Alzheimer's Disease
- Researchers reported progress on several potential drug therapies for people with Alzheimer's disease.
- SOURCE: G2C
- 2187. Alzheimer's disease - imaging test
- Professor Donna Wilcock discusses a new biological technique for diagnosing Alzheimer's disease using PET neuroimaging.
- SOURCE: G2C
- 2186. Alzheimer's disease - clinical testing
- Professor Donna Wilcock explains that Alzheimer's disease is diagnosed clinically by a battery of tests that can take a full day to administer.
- SOURCE: G2C
- 949. Hallmarks, Avoiding detection
- Bruce Stillman, Ph.D. is president and chief executive officer of Cold Spring Harbor Laboratory, explains that there are two adaptive immune responses, and those immune responses adapt to changes in cells in our body whether they be by infection or other.
- SOURCE: IC
- 2177. Cholinergic hypothesis of Alzheimer’s disease
- Professor Donna Wilcock dscusses the cholinergic hypothesis of Alzheimer's disease, which focuses on cholinergic neurons. The hypothesis has not been supported.
- SOURCE: G2C
- 2227. Alzheimer's disease
- An overview of Alzheimer's disease-related content on Genes to Cognition Online.
- SOURCE: G2C
- 2175. Alzheimer's disease medications - Aricept
- Professor Donna Wilcock explains that Aricept can only provide short-term benefit in treating Alzheimer's disease.
- SOURCE: G2C
- 15230. Holmes' conclusions at Buck vs. Bell, Paul Lombardo
- Paul Lombardo talks bout in the Supreme Court decision, Justice Holmes compared sterilization for feeblemindedness to a vaccination for smallpox.
- SOURCE: DNAi
